{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:35:11Z","timestamp":1782315311799,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["SL42765"],"award-info":[{"award-number":["SL42765"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00366-4","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T14:02:46Z","timestamp":1654264966000},"page":"1209-1219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Decision-Making Under Uncertainty in the Management of Spinal Muscular Atrophy: Results From DECISIONS-SMA Study"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-9886","authenticated-orcid":false,"given":"Gustavo","family":"Saposnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"D\u00edaz-Ab\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Bra\u00f1as-Pampill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"S\u00e1nchez-Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Cabello-Moruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Terzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Maurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"M\u00e1laga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"366_CR1","first-page":"1348","volume":"26","author":"JR Nance","year":"2020","unstructured":"Nance JR. Spinal muscular atrophy. Continuum (Minneap Minn). 2020;26:1348\u201368.","journal-title":"Continuum (Minneap Minn)"},{"key":"366_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831\u201346.","journal-title":"Neurol Clin"},{"key":"366_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejpn.2019.03.004","volume":"23","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Edstr\u00f6m J, Sejersen T, Tulinius M, Lochm\u00fcller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: a systematic review. Eur J Paediatr Neurol. 2019;23:347\u201356.","journal-title":"Eur J Paediatr Neurol"},{"key":"366_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12:124.","journal-title":"Orphanet J Rare Dis"},{"key":"366_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/mus.27358","volume":"64","author":"MS Cartwright","year":"2021","unstructured":"Cartwright MS, Upadhya S. Selecting disease-modifying medications in 5q spinal muscular atrophy. Muscle Nerve. 2021;64:404\u201312.","journal-title":"Muscle Nerve"},{"key":"366_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disord. 2018;28:197\u2013207.","journal-title":"Neuromuscular Disord"},{"key":"366_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","volume":"21","author":"MA Waldrop","year":"2019","unstructured":"Waldrop MA, Kolb SJ. Current treatment options in neurology-SMA therapeutics. Curr Treat Options Neurol. 2019;21:25.","journal-title":"Curr Treat Options Neurol"},{"key":"366_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fneur.2020.00783","volume":"11","author":"RS Finkel","year":"2020","unstructured":"Finkel RS, Schara-Schmidt U, Hagenacker T. Editorial: Spinal muscular atrophy: evolutions and revolutions of modern therapy. Front Neurol. 2020;11:783.","journal-title":"Front Neurol"},{"key":"366_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7:1\u201313.","journal-title":"J Neuromuscul Dis"},{"key":"366_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy\u2014insights and challenges in the treatment era. Nat Rev Neurol. 2020;16:706\u201315.","journal-title":"Nat Rev Neurol"},{"key":"366_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1017\/cjn.2018.371","volume":"46","author":"G Saposnik","year":"2019","unstructured":"Saposnik G. Applying behavioral economics and neuroeconomics to medical education and clinical care. Can J Neurol Sci. 2019;46:35\u20137.","journal-title":"Can J Neurol Sci"},{"key":"366_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264006","volume":"17","author":"G Saposnik","year":"2022","unstructured":"Saposnik G, D\u00edaz-Ab\u00f3s P, S\u00e1nchez-Men\u00e9ndez V, et al. Therapeutic decisions under uncertainty for spinal muscular atrophy: the DECISIONS-SMA study protocol. PLoS ONE. 2022;17: e0264006.","journal-title":"PLoS ONE"},{"key":"366_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","volume":"31","author":"N Gusset","year":"2021","unstructured":"Gusset N, Stalens C, Stumpe E, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord. 2021;31:419\u201330.","journal-title":"Neuromuscul Disord"},{"key":"366_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.clinthera.2019.03.012","volume":"41","author":"R Cruz","year":"2019","unstructured":"Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating benefit-risk decision-making in spinal muscular atrophy: a first-ever study to assess risk tolerance in the SMA patient community. Clin Ther. 2019;41:943\u201360.","journal-title":"Clin Ther"},{"key":"366_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17:68.","journal-title":"BMC Neurol"},{"key":"366_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40120-020-00229-w","volume":"10","author":"M Madruga-Garrido","year":"2021","unstructured":"Madruga-Garrido M, Vazquez-Costa JF, Medina-Cantillo J, et al. Design of a non-interventional study to validate a set of patient- and caregiver-oriented measurements to assess health outcomes in spinal muscular atrophy (SMA-TOOL Study). Neurol Ther. 2021;10:361\u201373.","journal-title":"Neurol Ther"},{"key":"366_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fneur.2018.00174","volume":"9","author":"G Saposnik","year":"2018","unstructured":"Saposnik G, Montalban X. Therapeutic inertia in the new landscape of multiple sclerosis care. Front Neurol. 2018;9:174.","journal-title":"Front Neurol"},{"key":"366_CR18","first-page":"65","volume":"8","author":"G Saposnik","year":"2017","unstructured":"Saposnik G, Sempere AP, Prefasi D, et al. Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol. 2017;8:65.","journal-title":"Front Neurol"},{"key":"366_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261050","volume":"16","author":"G Saposnik","year":"2021","unstructured":"Saposnik G, Del Rio B, Bueno-Gil G, et al. Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain. PLoS ONE. 2021;16: e0261050.","journal-title":"PLoS ONE"},{"key":"366_CR20","first-page":"1165","volume":"8","author":"M Annoussamy","year":"2020","unstructured":"Annoussamy M, Seferian AM, Daron A, et al. Natural history of type\u00a02 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2020;8:1165\u20137.","journal-title":"Ann Clin Transl Neurol"},{"key":"366_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, et al. Patterns of disease progression in type\u00a02 and 3 SMA: implications for clinical trials. Neuromuscul Disord. 2016;26:126\u201331.","journal-title":"Neuromuscul Disord"},{"key":"366_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, Ciafaloni E, Ashwal S, et al. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;91:923\u201333.","journal-title":"Neurology"},{"key":"366_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","volume":"7","author":"J Glascock","year":"2020","unstructured":"Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7:97\u2013100.","journal-title":"J Neuromuscul Dis"},{"key":"366_CR24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/jcm9072222","volume":"9","author":"S Messina","year":"2020","unstructured":"Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9:2222.","journal-title":"J Clin Med"},{"key":"366_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/00005650-199008000-00005","volume":"28","author":"MS Gerrity","year":"1990","unstructured":"Gerrity MS, DeVellis RF, Earp JA. Physicians\u2019 reactions to uncertainty in patient care. A new measure and new insights. Med Care. 1990;28:724\u201336.","journal-title":"Med Care"},{"key":"366_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF02250510","volume":"19","author":"MS Gerrity","year":"1995","unstructured":"Gerrity MS, White KP, DeVellis RF, Dittus RS. Physicians\u2019 reactions to uncertainty: refining the constructs and scales. Motiv Emot. 1995;19:175\u201391.","journal-title":"Motiv Emot"},{"key":"366_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/MLR.0000000000000157","volume":"52","author":"BA Cunningham","year":"2014","unstructured":"Cunningham BA, Bonham VL, Sellers SL, Yeh HC, Cooper LA. Physicians\u2019 anxiety due to uncertainty and use of race in medical decision making. Med Care. 2014;52:728\u201333.","journal-title":"Med Care"},{"key":"366_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","volume":"27","author":"F Rouault","year":"2017","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, et al. Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27:428\u201338.","journal-title":"Neuromuscul Disord"},{"key":"366_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/0883073818822900","volume":"34","author":"K Beernaert","year":"2019","unstructured":"Beernaert K, Lovgren M, Jeppesen J, et al. Parents\u2019 experiences of information and decision making in the care of their child with severe spinal muscular atrophy: a population survey. J Child Neurol. 2019;34:210\u20135.","journal-title":"J Child Neurol"},{"issue":"Suppl 1","key":"366_CR30","first-page":"103","volume":"40","author":"SH Lo","year":"2021","unstructured":"Lo SH, Lawrence C, Mart\u00ed Y, Caf\u00e9 A, Lloyd AJ. Patient and caregiver treatment preferences in type\u00a02 and non-ambulatory type\u00a03 spinal muscular atrophy: a discrete choice experiment survey in five European countries. Pharmacoeconomics. 2021;40(Suppl 1):103\u201315.","journal-title":"Pharmacoeconomics"},{"key":"366_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, et al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16:36.","journal-title":"Orphanet J Rare Dis"},{"key":"366_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1287\/orsc.2019.1300","volume":"31","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez C, \u00c5stebro T, Obloj T. The impact of overconfidence and ambiguity attitude on market entry. Organ Sci. 2020;31:308\u201329.","journal-title":"Organ Sci"},{"key":"366_CR33","doi-asserted-by":"publisher","DOI":"10.3758\/s13428-021-01635-0","author":"Z Ellerby","year":"2021","unstructured":"Ellerby Z, Wagner C, Broomell SB. Capturing richer information: on establishing the validity of an interval-valued survey response mode. Behav Res Methods. 2021. https:\/\/doi.org\/10.3758\/s13428-021-01635-0.","journal-title":"Behav Res Methods"},{"key":"366_CR34","doi-asserted-by":"crossref","unstructured":"Wadman RI, van der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020;1(1):CD006282-CD.","DOI":"10.1002\/14651858.CD006282.pub5"},{"key":"366_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","volume":"28","author":"J Kirschner","year":"2020","unstructured":"Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38\u201343.","journal-title":"Eur J Paediatr Neurol"},{"key":"366_CR36","unstructured":"Pitarch-Castellano I, Cabrera-Serrano M, Calvo-Medina R, et al. Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus). Neurolog\u00eda. 2022:S2173-5808(22)00012-8."},{"key":"366_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejpn.2020.11.003","volume":"30","author":"N Gusset","year":"2021","unstructured":"Gusset N, Erbas Y, Germanenko O, Rucinski K, Stumpe E, de Lemus M. A decision for life\u2014treatment decisions in newly diagnosed families with spinal muscular atrophy (SMA). Eur J Paediatr Neurol. 2021;30:105\u20137.","journal-title":"Eur J Paediatr Neurol"},{"key":"366_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12911-016-0377-1","volume":"16","author":"G Saposnik","year":"2016","unstructured":"Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016;16:138.","journal-title":"BMC Med Inform Decis Mak"},{"key":"366_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/15265161.2016.1159750","volume":"16","author":"JS Blumenthal-Barby","year":"2016","unstructured":"Blumenthal-Barby JS. Biases and heuristics in decision making and their impact on autonomy. Am J Bioeth. 2016;16:5\u201315.","journal-title":"Am J Bioeth"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00366-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T01:16:20Z","timestamp":1659143780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00366-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00366-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Roche Medical Department Spain (SL42765). The sponsor also funded the journal\u2019s Rapid Service fee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"All authors made a significant contribution to the work reported, whether in study conception, design, execution, acquisition of data, analysis and interpretation, or in all these areas; all took part in drafting, revising or critically reviewing the article; all gave final approval of the version to be published; all have agreed on the journal to which the article has been submitted; and all agree to be accountable for all aspects of the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This study was funded by Roche Medical Department Spain (SL42765) and supported by NeuroeconSolutions. The funding source had no role in the design, analysis and interpretation of the data, review or approval of the manuscript, and decision to submit for publication. Gustavo Saposnik received unrestricted grants and personal fees from Hoffman La Roche (Canada) and Roche Farma (Spain), and reported being supported by the Heart and Stroke Foundation of Canada Scientist Award following an open peer-reviewed competition. Paola D\u00edaz-Ab\u00f3s, Mar\u00eda Bra\u00f1as-Pampill\u00f3n, Victoria S\u00e1nchez-Men\u00e9ndez, Rosana Cabello-Moruno and Jorge Maurino are employees of Roche Farma Spain. Ana Camacho, Mar\u00eda Terzaghi, and Ignacio M\u00e1laga declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The study was approved by the ethics committee of Hospital Cl\u00ednico San Carlos, Madrid, Spain (reference 21\/313-E), and performed in accordance with the 1964 Helsinki Declaration and its later amendments. Participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"Qualified researchers may request access to individual patient-level data through the corresponding author. The datasets generated during the analysis of the study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}